Climb Bio (CLYM) Set to Release Earnings on Wednesday

Climb Bio (NASDAQ:CLYM) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.20) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. On average, analysts expect Climb Bio to post ($0.80) EPS for the current fiscal year and ($1.01) EPS for the next fiscal year.

Climb Bio Trading Up 0.1%

NASDAQ:CLYM opened at $9.75 on Wednesday. The company has a 50-day moving average price of $12.32 and a 200-day moving average price of $10.39. Climb Bio has a 12 month low of $1.63 and a 12 month high of $18.33. The stock has a market cap of $560.04 million, a price-to-earnings ratio of -11.75 and a beta of 0.01.

Insider Activity at Climb Bio

In other news, Director Stephen Thomas sold 100,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total value of $1,367,000.00. Following the sale, the director directly owned 467,969 shares of the company’s stock, valued at $6,397,136.23. This represents a 17.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on CLYM shares. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Climb Bio in a research note on Tuesday, October 20th. They issued a “buy” rating and a $28.00 price target for the company. Truist Financial lifted their price objective on Climb Bio from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada began coverage on Climb Bio in a report on Monday, August 3rd. They set an “outperform” rating and a $23.00 target price on the stock. Mizuho raised Climb Bio to a “strong-buy” rating in a research report on Wednesday, September 16th. Finally, Guggenheim restated a “buy” rating on shares of Climb Bio in a research note on Monday, October 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Climb Bio has an average rating of “Buy” and an average price target of $27.64.

About Climb Bio

Climb Bio, Inc (NASDAQ: CLYM) is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company is working to create medicines that target B cells, which play a central role in the immune responses associated with many autoimmune disorders.

Climb Bio’s lead investigational product, CLYM116, is a fully human anti-CD19 monoclonal antibody designed to selectively deplete B cells. The therapy is being evaluated in clinical development for autoimmune conditions, including primary membranous nephropathy, a kidney disorder in which abnormal immune activity can damage the kidneys.

As a development-stage biotechnology company, Climb Bio’s activities are centered on research, clinical trials and the potential commercialization of its pipeline rather than on marketed products.